| All patients | Original cohort, N, % | Crude analysis OR (95% CI) | Multivariable analysis AOR (95% CI)a | After adjustment of IPW, % | OR (95% CI)b | ||
---|---|---|---|---|---|---|---|---|
n-TTM | h-TTM | n-TTM | h-TTM | |||||
N = 890 | N = 249 | N = 641 |  |  | ||||
30-Day neurological favourable outcome | 143 (16.1) | 41 (16.5) | 102 (15.9) | 0.96 (0.65–1.43) | 0.91 (0.58–1.43) | 15.3 | 15.4 | 1.01 (0.67–1.54) |
30-Day survival | 318 (35.7) | 88 (35.3) | 230 (35.9) | 1.02 (0.75–1.39) | 1.00 (0.71–1.41) | 34.3 | 35.5 | 1.05 (0.76–1.46) |
Completion of TTM | 566 (63.6) | 163 (65.5) | 403 (62.9) | 0.89 (0.66–1.21) | 0.81 (0.57–1.16) | 67.0 | 62.2 | 0.81 (0.58–1.13) |